Homologous and heterologous protection of mice with group A streptococcal M protein vaccines
- PMID: 319054
- PMCID: PMC421334
- DOI: 10.1128/iai.15.1.104-108.1977
Homologous and heterologous protection of mice with group A streptococcal M protein vaccines
Abstract
Purified streptococcal M proteins precipitated with alum (APM) were used to immunize mice. A trivalent vaccine of serotypes 1, 3, and 12 protected mice against challenges by homologous live streptococci and also conferred protection against serotypes 6 and 14 but not against a strain of group B streptococci. Monovalent APM vaccines afforded homologous protection and restricted heterologous protection. The extent of heterologous protection was a function of serotype combinations and was also dose dependent. Rabbit antisera exhibiting strong opsonic activities were active in vitro and in passive mouse protection only for homologous serotypes. Mouse antisera did not passively transfer protection and were not bactericidal in vitro. It was concluded that homologous and heterologous active mouse protection was most likely a result of shared antigenic determinants of the various M proteins although protection of mice could not be measured as a function of circulating anti-M antibodies.
Similar articles
-
Synthetic peptide vaccine against mucosal colonization by group A streptococci. I. Protection against a heterologous M serotype with shared C repeat region epitopes.J Immunol. 1990 Aug 15;145(4):1251-6. J Immunol. 1990. PMID: 1696296
-
Multivalent group A streptococcal vaccine designed to optimize the immunogenicity of six tandem M protein fragments.Vaccine. 1999 Jan;17(2):193-200. doi: 10.1016/s0264-410x(98)00150-9. Vaccine. 1999. PMID: 9987154
-
Human immune response to immunization with a structurally defined polypeptide fragment of streptococcal M protein.J Exp Med. 1979 Oct 1;150(4):862-77. doi: 10.1084/jem.150.4.862. J Exp Med. 1979. PMID: 390084 Free PMC article.
-
Protection against streptococcal pharyngeal colonization with vaccines composed of M protein conserved regions.Adv Exp Med Biol. 1991;303:159-67. doi: 10.1007/978-1-4684-6000-1_17. Adv Exp Med Biol. 1991. PMID: 1805563 Review. No abstract available.
-
Current status of group A streptococcal vaccine development.Adv Exp Med Biol. 2008;609:53-63. doi: 10.1007/978-0-387-73960-1_5. Adv Exp Med Biol. 2008. PMID: 18193657 Review.
Cited by
-
Conservation of protective and nonprotective epitopes in M proteins of group A streptococci.Infect Immun. 1988 Aug;56(8):2198-204. doi: 10.1128/iai.56.8.2198-2204.1988. Infect Immun. 1988. PMID: 2456272 Free PMC article.
-
Heterogeneity of type-specific and cross-reactive antigenic determinants within a single M protein of group A streptococci.J Exp Med. 1980 May 1;151(5):1026-38. doi: 10.1084/jem.151.5.1026. J Exp Med. 1980. PMID: 6154764 Free PMC article.
-
Streptococcal M protein: molecular design and biological behavior.Clin Microbiol Rev. 1989 Jul;2(3):285-314. doi: 10.1128/CMR.2.3.285. Clin Microbiol Rev. 1989. PMID: 2670192 Free PMC article. Review.
-
Recent advances in rheumatic fever control and future prospect: a WHO memorandum.Bull World Health Organ. 1978;56(6):887-912. Bull World Health Organ. 1978. PMID: 310731 Free PMC article.
-
[Recent progress in the fight against acute arthritic rheumatism and future perspectives: WHO Memorandum].Bull World Health Organ. 1979;57(2):235-64. Bull World Health Organ. 1979. PMID: 312158 Free PMC article. No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources